Recombinant Rabbit Monoclonal Anti- CDK4 antibody

Catalog# BRM1139-1

Lot # Check on the product label

Size 50 μl

Isotype IgG

Host Rabbit

Reactivity 

Human, mouse, rat

Immunogen Recombinant protein of human Cdk4.

Clone ID  1C11

Synonyms CDK4; CMM3; PSK-J3; cyclin-dependent kinase 4; cyclin dependent kinase 4

Content Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% New type preservative N and 0.05% BSA.

Recommend Application

Western Blot, WB (1:1000)

Immunocytochemistry, ICC/IF (1:100-200)

Immunoprecipitation, IP (1:50)

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Storage Instruction 

Ship at 2-8°C, when receipt, aliquot and store at -20°C for one year.

Avoid repeated freeze and thaw cycles.

Background

Cyclin-dependent kinase 4 also known as cell division protein kinase 4 is an enzyme that in humans is encoded by the CDK4 gene. CDK4 is a member of the cyclin-dependent kinase family. The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16INK4a. This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb).[4] Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition.

Reference

1. Sheppard, K. E.; McArthur, G. A. (2013-10-01). "The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma". Clinical Cancer Research. 19 (19): 5320–5328.

2. Sobhani; D’Angelo; Pittacolo; Roviello; Miccoli; Corona; Bernocchi; Generali; Otto (2019-04-06). "Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer". Cells. 8 (4): 321.